Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y 12 inhibitor has been the standard of care to prevent thrombotic events in patients with acute coronary syndrome (ACS) undergoing ...
Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...
Patients with left main coronary artery disease who present with ACS fare just as well when treated with PCI as they do with CABG surgery, according to results of a new study. While ACS patients had ...
PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended ...
ORLANDO — The risk for clinical events at 30 days in a trial that enrolled a broad population with acute coronary syndrome (ACS) was not affected by administration of two 80-mg loading doses of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Despite fewer bleeding events, 1-month ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Long-term ticagrelor monotherapy after ...
ACS, which includes heart attack and unstable angina (chest pain), affects more than 1.5 million people in the United States annually, many of whom are managed with PCI. (1) In 2009, an estimated ...
"This study suggests that the ARC-HBR and PRECISE-DAPT bleeding criteria can be used to risk stratify patients and guide the therapeutic selection to lower the bleeding risk. For instance, we found ...
Bivalirudin Superior to Heparin in ‘Real World’ Patients with ACS Undergoing PCI + Coronary Stenting
SAN FRANCISCO, CA—Use of bivalirudin alone was superior to heparin alone with respect to all-cause mortality in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHILADELPHIA -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback